Tocagen (TOCA) to Release Quarterly Earnings on Tuesday

Share on StockTwits

Tocagen (NASDAQ:TOCA) will announce its earnings results after the market closes on Tuesday, November 12th. Analysts expect the company to announce earnings of ($0.68) per share for the quarter.

Tocagen (NASDAQ:TOCA) last announced its earnings results on Thursday, August 8th. The company reported ($0.72) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.76) by $0.04. The company had revenue of $0.01 million for the quarter, compared to analyst estimates of $0.50 million. Tocagen had a negative return on equity of 115.81% and a negative net margin of 300.42%. On average, analysts expect Tocagen to post $-3 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Shares of NASDAQ TOCA opened at $0.63 on Friday. Tocagen has a 52-week low of $0.53 and a 52-week high of $14.75. The firm has a market cap of $15.43 million, a price-to-earnings ratio of -0.26 and a beta of 3.89. The business’s 50 day moving average is $0.65 and its two-hundred day moving average is $4.48. The company has a quick ratio of 4.21, a current ratio of 4.21 and a debt-to-equity ratio of 0.86.

TOCA has been the subject of several recent research reports. Zacks Investment Research upgraded shares of Tocagen from a “hold” rating to a “buy” rating and set a $1.00 target price for the company in a research note on Wednesday, September 18th. Citigroup downgraded shares of Tocagen from a “buy” rating to a “neutral” rating and decreased their target price for the stock from $20.00 to $1.00 in a research note on Friday, September 13th. Chardan Capital downgraded shares of Tocagen to a “hold” rating and set a $1.00 target price for the company. in a research note on Thursday, October 3rd. Cantor Fitzgerald reiterated a “neutral” rating on shares of Tocagen in a research note on Thursday, October 17th. Finally, ValuEngine upgraded shares of Tocagen from a “hold” rating to a “buy” rating in a research note on Thursday, August 1st. Nine equities research analysts have rated the stock with a hold rating and three have given a buy rating to the stock. Tocagen currently has a consensus rating of “Hold” and an average target price of $10.26.

Tocagen Company Profile

Tocagen Inc, a clinical-stage cancer-selective gene therapy company, focuses on developing and commercializing product candidates designed to activate a patient's immune system against their cancer. Its cancer-selective gene therapy platform is built on retroviral replicating vectors (RRVs), which are designed to deliver therapeutic genes into the DNA of cancer cells.

See Also: Understanding the Price to Earnings Ratio (PE)

Earnings History for Tocagen (NASDAQ:TOCA)

Receive News & Ratings for Tocagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tocagen and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2019 BBNS.